ATAI Life Sciences N.V. (now Atai Beckley N.V.) is a clinical-stage biopharmaceutical company developing transformative mental health treatments. In March 2025, the company allocated $5M of existing cash reserves to purchase Bitcoin as a treasury diversification strategy.